Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O75715

UPID:
GPX5_HUMAN

ALTERNATIVE NAMES:
Epididymis-specific glutathione peroxidase-like protein; Glutathione peroxidase 5

ALTERNATIVE UPACC:
O75715; A1A4Y0

BACKGROUND:
Epididymis-specific glutathione peroxidase-like protein, known for its antioxidative properties, is essential in cellular defense against oxidative stress. By reducing harmful peroxides with glutathione, it prevents oxidative damage in cells and enzymes. Its unique function in the epididymis highlights its importance in the male reproductive system, protecting spermatozoa from oxidative injuries.

THERAPEUTIC SIGNIFICANCE:
Exploring the antioxidative mechanisms of Epididymis-specific glutathione peroxidase-like protein offers promising avenues for therapeutic interventions. Its role in maintaining sperm integrity through oxidative stress protection could lead to novel treatments for male infertility and enhance reproductive health outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.